T. Rowe Price Associates
ASTH icon

T. Rowe Price Associates’s Astrana Health ASTH Stock Holding History

T. Rowe Price Associates’s Portfolio ASTH Stock Details ASTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Buy
49,418
+7,160
+17% +$170K ﹤0.01% 2058
2025
Q4 		$1.05M Buy
42,258
+1,562
+4% +$41.5K ﹤0.01% 2069
2025
Q3 		$1.15M Buy
40,696
+5,113
+14% +$139K ﹤0.01% 1997
2025
Q2 		$886K Sell
35,583
-515
-1% -$14.5K ﹤0.01% 2040
2025
Q1 		$1.12M Buy
36,098
+3,143
+10% +$105K ﹤0.01% 1898
2024
Q4 		$1.04M Sell
32,955
-706
-2% -$33.5K ﹤0.01% 1947
2024
Q3 		$1.95M Buy
33,661
+986
+3% +$48.4K ﹤0.01% 1649
2024
Q2 		$1.33M Buy
32,675
+1,305
+4% +$51.8K ﹤0.01% 1765
2024
Q1 		$1.32M Buy
31,370
+1,587
+5% +$61.9K ﹤0.01% 1769
2023
Q4 		$1.14M Buy
29,783
+1,086
+4% +$36.2K ﹤0.01% 1804
2023
Q3 		$886K Buy
28,697
+1,720
+6% +$59.4K ﹤0.01% 1854
2023
Q2 		$853K Buy
26,977
+1,182
+5% +$40.5K ﹤0.01% 1883
2023
Q1 		$941K Buy
25,795
+968
+4% +$33.9K ﹤0.01% 1820
2022
Q4 		$735K Buy
24,827
+3,248
+15% +$104K ﹤0.01% 1945
2022
Q3 		$842K Buy
21,579
+3,731
+21% +$171K ﹤0.01% 1845
2022
Q2 		$689K Sell
17,848
-438
-2% -$16.7K ﹤0.01% 2073
2022
Q1 		$886K Buy
18,286
+3,166
+21% +$163K ﹤0.01% 2062
2021
Q4 		$1.11M Buy
15,120
+1,888
+14% +$155K ﹤0.01% 1981
2021
Q3 		$1.21M Buy
+13,232
New +$1.13M ﹤0.01% 1960

Other funds holding ASTH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

T. Rowe Price Associates's ASTH Position: Q1 2026 in Review

T. Rowe Price Associates increased its Astrana Health (ASTH) stake by 17% in Q1 2026, buying an estimated $170K and bringing the position to 49,418 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2058.

T. Rowe Price Associates first reported a position in ASTH in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.95M in Q3 2024. 171 funds tracked by Wall St. Rank hold ASTH as of Q1 2026.

  • T. Rowe Price Associates held 49,418 shares of Astrana Health worth $1.21M as of Q1 2026.
  • T. Rowe Price Associates bought 7,160 Astrana Health shares in Q1 2026, an estimated $170K.
  • Astrana Health made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2058 holding.
  • T. Rowe Price Associates first reported a position in Astrana Health in Q3 2021 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Astrana Health position peaked at $1.95M in Q3 2024.
  • 171 funds tracked by Wall St. Rank held Astrana Health as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.